MedTrace Logo

Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria

NCT02841865 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2020-03-24

No results posted yet for this study

Summary

The Response Evaluation Criteria in Solid Tumors (RECIST), based on differences in tumor size, has been considered as a reproducible method that facilitates not only the measurement of the mass but the evaluation of response to given treatments; while classic chemotherapy induces a reduction of the tumor, new target therapies frequently produce the stabilization of the disease or a delayed progression. These new therapeutic alternatives have shade light on the limitations of the RECIST criteria, since the response to these type of treatments are basically associated with changes on the radiological characteristics of the tumor, as well as other findings in functional imaging.

This study is aimed to compare the response rates according both Choi and RECIST criteria.

Conditions

  • Pancreatic Neuroendocrine Tumors

Sponsors & Collaborators

  • Grupo Espanol de Tumores Neuroendocrinos

    lead OTHER

Principal Investigators

  • María del Pilar Solís Hernández, M.D. · Hospital Universitario Central de Asturias

  • Paula Jiménez Fonseca, M.D. · Hospital Universitario Central de Asturias

  • David Calvo Temprano, M.D. · Hospital Universitario Central de Asturias

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-24
Primary Completion
2017-12-31
Completion
2018-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02841865 on ClinicalTrials.gov